AIM
VKTX icon

Aigen Investment Management’s Viking Therapeutics VKTX Stock Holding History

Aigen Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,103
Closed -$355K – 800
2025
Q4 		$355K Buy
+10,103
New +$358K 0.08% 307
2025
Q2 		– Sell
-13,780
Closed -$333K – 1089
2025
Q1 		$333K Buy
+13,780
New +$436K 0.05% 467
2023
Q4 		– Sell
-13,396
Closed -$148K – 1111
2023
Q3 		$148K Buy
+13,396
New +$192K 0.03% 712

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Aigen Investment Management's VKTX Position: Q1 2026 in Review

Aigen Investment Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 10,103 shares — an estimated $355K sold.

Aigen Investment Management first reported a position in VKTX in Q3 2023 and held it in 3 quarters. The position peaked at $355K in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Aigen Investment Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 10,103 Viking Therapeutics shares in Q1 2026, an estimated $355K.
  • Aigen Investment Management first reported a position in Viking Therapeutics in Q3 2023 and held it in 3 quarters.
  • Aigen Investment Management's Viking Therapeutics position peaked at $355K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.